PeerCurrent.com|Stay current with the people and research shaping what comes next.

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Disease

Rechallenge

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials1 Reviews Guidelines

Latest

Everything in the corpus, newest first.

AUG 20, 2026 · OBSERVATIONAL STUDY

PD-L1 Inhibitor Rechallenge After Immunotherapy-Related Pneumonitis in Patients With Lung Cancer

ClinicalTrials.gov

This is an observational registry study in recruitment with no reported results; it describes a planned comparison of checkpoint inhibitor rechallenge strategies in lung cancer patients with prior pneumonitis, addressing an important safety question but delivering no outcome data yet.

PreliminaryPD-L1 Inhibitor Rechallenge Nanfang Hospital, Southern Medical University PD-1 Inhibitor Rechallenge

Reported

Planned sample size150

Primary outcome measureRecurrence rate of checkpoint inhibitor pne…

Follow-up duration for secondary…24 weeks

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support